(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Parents who delay baby's first vaccines also likely to skip measles shots - 26 Shades Brands For Seniors
- 3Ober Gabelhorn glacier reveals remains of man missing for over three decades
- 42024's Hot Games: Must-Play Titles of the Year
- 5Satellite constellations could obscure most space telescope observations by late 2030s: 'That part of the image will be forever lost'
- Single women risk rape and exploitation in search for better life in Europe
- Meet ‘NASA Mike,’ who’s done 105,000 handstands around the world
- The Quadrantid meteor shower peaks tonight, but will the full 'Wolf Moon' outshine the show?
- CMA Awards 2025: Full list of nominations, from Entertainer of the Year to Album of the Year
- 5 Arising Professions in Environmentally friendly power
- Cocoa Prices Undercut Amid the Prospects of Abundant Supplies
- A Manual for Well known Western television Series
- Satellite space quiz: What's orbiting Earth?
- 3 back-to-back storms forecast to bring snow and surges of cold air across the Midwest to the Northeast
